SCYNEXIS (SCYX) Competitors $0.70 +0.00 (+0.43%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$0.71 +0.01 (+1.00%) As of 07/11/2025 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SCYX vs. BHST, GNLX, TARA, ATOS, HURA, PROC, CCCC, ANIX, MIST, and MCRBShould you be buying SCYNEXIS stock or one of its competitors? The main competitors of SCYNEXIS include BioHarvest Sciences (BHST), Genelux (GNLX), Protara Therapeutics (TARA), Atossa Genetics (ATOS), TuHURA Biosciences (HURA), Procaps Group (PROC), C4 Therapeutics (CCCC), Anixa Biosciences (ANIX), Milestone Pharmaceuticals (MIST), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical products" industry. SCYNEXIS vs. Its Competitors BioHarvest Sciences Genelux Protara Therapeutics Atossa Genetics TuHURA Biosciences Procaps Group C4 Therapeutics Anixa Biosciences Milestone Pharmaceuticals Seres Therapeutics SCYNEXIS (NASDAQ:SCYX) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership. Which has more volatility and risk, SCYX or BHST? SCYNEXIS has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500. Comparatively, BioHarvest Sciences has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Do analysts prefer SCYX or BHST? BioHarvest Sciences has a consensus price target of $13.67, indicating a potential upside of 90.34%. Given BioHarvest Sciences' stronger consensus rating and higher probable upside, analysts clearly believe BioHarvest Sciences is more favorable than SCYNEXIS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SCYNEXIS 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00BioHarvest Sciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in SCYX or BHST? 54.4% of SCYNEXIS shares are held by institutional investors. 4.9% of SCYNEXIS shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has preferable earnings & valuation, SCYX or BHST? BioHarvest Sciences has higher revenue and earnings than SCYNEXIS. BioHarvest Sciences is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSCYNEXIS$3.75M7.31-$21.29M-$0.56-1.26BioHarvest Sciences$25.19M4.68-$12.91M-$0.50-14.36 Does the media refer more to SCYX or BHST? In the previous week, BioHarvest Sciences had 1 more articles in the media than SCYNEXIS. MarketBeat recorded 2 mentions for BioHarvest Sciences and 1 mentions for SCYNEXIS. SCYNEXIS's average media sentiment score of 1.87 beat BioHarvest Sciences' score of 0.93 indicating that SCYNEXIS is being referred to more favorably in the media. Company Overall Sentiment SCYNEXIS Very Positive BioHarvest Sciences Positive Is SCYX or BHST more profitable? BioHarvest Sciences has a net margin of -31.30% compared to SCYNEXIS's net margin of -1,030.04%. SCYNEXIS's return on equity of -53.47% beat BioHarvest Sciences' return on equity.Company Net Margins Return on Equity Return on Assets SCYNEXIS-1,030.04% -53.47% -32.86% BioHarvest Sciences -31.30%-307.04%-33.21% SummarySCYNEXIS and BioHarvest Sciences tied by winning 8 of the 16 factors compared between the two stocks. Get SCYNEXIS News Delivered to You Automatically Sign up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SCYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCYX vs. The Competition Export to ExcelMetricSCYNEXISMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.31M$2.45B$5.61B$9.11BDividend YieldN/A1.79%5.24%4.02%P/E Ratio-1.269.4227.9620.25Price / Sales7.31729.02430.8999.65Price / CashN/A165.3637.4658.16Price / Book0.484.608.045.49Net Income-$21.29M$31.26M$3.18B$250.27M7 Day Performance-3.83%4.80%3.67%4.80%1 Month Performance-14.48%5.42%4.09%7.68%1 Year Performance-68.05%-4.36%29.58%16.36% SCYNEXIS Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCYXSCYNEXIS0.9058 of 5 stars$0.70+0.4%N/A-68.3%$27.31M$3.75M-1.2660Positive NewsBHSTBioHarvest SciencesN/A$7.06+2.3%$13.67+93.6%N/A$113.33M$27.70M-14.12N/AHigh Trading VolumeGNLXGenelux1.2536 of 5 stars$2.90-2.7%$17.75+512.1%+34.5%$112.45MN/A-3.3010News CoverageAnalyst UpgradeGap DownTARAProtara Therapeutics1.9166 of 5 stars$2.80-3.1%$20.50+632.1%+30.3%$111.50MN/A-1.6330ATOSAtossa Genetics2.8879 of 5 stars$0.85-0.4%$6.17+629.1%-26.7%$109.68MN/A-4.038HURATuHURA Biosciences1.3186 of 5 stars$2.40-3.2%$12.67+427.8%N/A$108.33MN/A0.00N/APROCProcaps GroupN/A$0.95-40.3%N/A-62.2%$107.18M$409.92M0.004,900Gap DownHigh Trading VolumeCCCCC4 Therapeutics3.0309 of 5 stars$1.52+2.7%$12.00+689.5%-56.4%$105.09M$35.58M-1.03150Positive NewsANIXAnixa Biosciences3.0501 of 5 stars$3.21-0.6%$9.00+180.4%+25.1%$104.04M$210K-8.455News CoverageMISTMilestone Pharmaceuticals2.8124 of 5 stars$2.17+11.9%$7.00+222.6%+3.3%$103.72M$1M-2.7830Trending NewsGap DownHigh Trading VolumeMCRBSeres Therapeutics3.3243 of 5 stars$10.85-8.6%$73.67+579.0%-35.7%$103.65M$126.32M-2.36330Positive News Related Companies and Tools Related Companies BHST Alternatives GNLX Alternatives TARA Alternatives ATOS Alternatives HURA Alternatives PROC Alternatives CCCC Alternatives ANIX Alternatives MIST Alternatives MCRB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCYX) was last updated on 7/12/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump’s whole-government AI plans leakedThe New Elon Musk is officially stepping back from his day-to-day duties with DOGE. At least, that's the s...Altimetry | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SCYNEXIS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SCYNEXIS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SCYX Stock Alerts